MCID: RTN022
MIFTS: 38

Retinal Vein Occlusion malady

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Retinal Vein Occlusion

Aliases & Descriptions for Retinal Vein Occlusion:

Name: Retinal Vein Occlusion 38 12 52 42 14 69
Occlusion, of Retinal Vein 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1727
MeSH 42 D012170
NCIt 47 C34981
SNOMED-CT 64 46085004
UMLS 69 C0035328

Summaries for Retinal Vein Occlusion

MalaCards based summary : Retinal Vein Occlusion, also known as occlusion, of retinal vein, is related to central retinal vein occlusion and partial of retinal vein occlusion. An important gene associated with Retinal Vein Occlusion is VEGFA (Vascular Endothelial Growth Factor A). The drugs Bevacizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and bone.

Related Diseases for Retinal Vein Occlusion

Diseases in the Retinal Vein Occlusion family:

Central Retinal Vein Occlusion

Diseases related to Retinal Vein Occlusion via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
id Related Disease Score Top Affiliating Genes
1 central retinal vein occlusion 12.6
2 partial of retinal vein occlusion 12.1
3 retinitis 11.2
4 endotheliitis 10.5
5 hyperhomocysteinemia 10.3
6 chorioretinitis 10.3
7 retinal artery occlusion 10.2
8 choroiditis 10.2
9 neovascular glaucoma 10.2
10 retinal detachment 10.2
11 ischemia 10.1
12 thrombophilia 10.1
13 macular holes 10.1
14 branch retinal artery occlusion 10.1
15 neuropathy 10.1
16 central retinal artery occlusion 10.1
17 vasculitis 10.0
18 ischemic optic neuropathy 10.0
19 protein s deficiency 10.0
20 tuberculosis 10.0
21 diabetic macular edema 10.0
22 retinal vasculitis 10.0
23 purpura 10.0
24 vitreous detachment 10.0
25 thrombosis 10.0
26 cytomegalovirus retinitis 10.0
27 leukemia 10.0
28 retinal ischemia 10.0
29 thrombotic thrombocytopenic purpura 10.0
30 rubeosis iridis 9.9
31 ocular hypertension 9.9
32 sleep apnea 9.9
33 myocardial infarction 9.9
34 retinal vascular occlusion 9.9
35 systemic lupus erythematosus 9.9
36 atherosclerosis 9.9
37 hepatitis c 9.9
38 hepatitis 9.9
39 myeloid leukemia 9.9
40 lupus erythematosus 9.9
41 open-angle glaucoma 9.9
42 multiple myeloma 9.9
43 psoriasis 9.9
44 ulcerative colitis 9.8
45 pneumonia 9.8
46 cryoglobulinemia 9.8
47 hemoglobinuria 9.8
48 antiphospholipid syndrome 9.8
49 rheumatoid arthritis 9.8
50 deficiency anemia 9.8

Graphical network of the top 20 diseases related to Retinal Vein Occlusion:



Diseases related to Retinal Vein Occlusion

Symptoms & Phenotypes for Retinal Vein Occlusion

Drugs & Therapeutics for Retinal Vein Occlusion

Drugs for Retinal Vein Occlusion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Glucosamine Approved, Nutraceutical Phase 4 3416-24-8 439213
7 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
8 Mitogens Phase 4,Phase 3,Phase 1,Phase 2
9 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
12 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
17 triamcinolone acetonide Phase 4,Phase 3,Phase 2,Phase 1
18 Triamcinolone diacetate Phase 4,Phase 3,Phase 2,Phase 1
19 Triamcinolone hexacetonide Phase 4,Phase 3,Phase 2,Phase 1
20 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
22 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
23 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
24 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 3,Phase 1
25 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
26 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
27 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
29
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2
31 Fibrinolytic Agents Phase 4,Phase 3,Phase 1
32 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
33 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
34
Lactitol Phase 4 585-86-4 3871
35 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
36 Mitomycins Phase 4
37 Anticoagulants Phase 4,Phase 3
38 Glucuronyl glucosamine glycan sulfate Phase 4
39 Hypoglycemic Agents Phase 4
40 Dermatologic Agents Phase 4,Phase 1,Phase 2
41 Photosensitizing Agents Phase 4
42 histidine Nutraceutical Phase 4
43
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
44
Ephedrine Approved Phase 2, Phase 3 299-42-3 9294
45
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
47
Pseudoephedrine Approved Phase 2, Phase 3 90-82-4 7028
48
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
49
Ethanol Approved Phase 3 64-17-5 702
50
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872

Interventional clinical trials:

(show top 50) (show all 223)
id Name Status NCT ID Phase
1 Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy Unknown status NCT01857544 Phase 4
2 Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO Unknown status NCT00566761 Phase 4
3 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4
4 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4
5 Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion Completed NCT01448018 Phase 4
6 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion Completed NCT01085734 Phase 4
7 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4
8 NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4
9 Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion Completed NCT01427751 Phase 4
10 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion Completed NCT01277302 Phase 4
11 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4
12 Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO Completed NCT01580020 Phase 4
13 Dexamethasone-implant for the Treatment of RVO Completed NCT01767545 Phase 4
14 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4
15 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
16 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4
17 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4
18 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4
19 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
20 Retinal Sensitivity in BRVO After Anti-VEGF Therapy Recruiting NCT02527733 Phase 4
21 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Recruiting NCT01827722 Phase 4
22 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Recruiting NCT02800642 Phase 4
23 Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety Recruiting NCT02953938 Phase 4
24 Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium Recruiting NCT01573572 Phase 4
25 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4
26 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Recruiting NCT02684084 Phase 4
27 Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Active, not recruiting NCT01795209 Phase 4
28 Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen Active, not recruiting NCT02274259 Phase 4
29 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4
30 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4
31 Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept Not yet recruiting NCT03056079 Phase 4
32 Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab Not yet recruiting NCT03056092 Phase 4
33 Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) Unknown status NCT01635803 Phase 2, Phase 3
34 Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO) Unknown status NCT01189526 Phase 3
35 Atorvastatin for the Treatment of Retinal Vein Occlusion Unknown status NCT00517257 Phase 3
36 Effect of Avastin in Juxtafoveal Telangiectasias Unknown status NCT00406380 Phase 3
37 Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion Completed NCT01599650 Phase 3
38 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
39 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3
40 Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Completed NCT00970957 Phase 3
41 Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion Completed NCT01377597 Phase 3
42 Ozurdex for Retinal Vein Occlusion Study (ORVO Study) Completed NCT01790685 Phase 2, Phase 3
43 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3
44 The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study Completed NCT00105027 Phase 3
45 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3
46 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed NCT01976312 Phase 3
47 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion Completed NCT01198327 Phase 3
48 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) Completed NCT00943072 Phase 3
49 Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) Completed NCT01512901 Phase 2, Phase 3
50 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Completed NCT01449682 Phase 3

Search NIH Clinical Center for Retinal Vein Occlusion

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Vein Occlusion cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Vein Occlusion:
Bone marrow-derived hematopoietic stem cells for retinopathy
Embryonic/Adult Cultured Cells Related to Retinal Vein Occlusion:
Bone marrow-derived hematopoietic CD34+ progenitors PMIDs: 22247454
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 22247454

Cochrane evidence based reviews: retinal vein occlusion

Genetic Tests for Retinal Vein Occlusion

Anatomical Context for Retinal Vein Occlusion

MalaCards organs/tissues related to Retinal Vein Occlusion:

39
Eye, Endothelial, Bone, Retina, Myeloid, Testes, Monocytes

Publications for Retinal Vein Occlusion

Articles related to Retinal Vein Occlusion:

(show top 50) (show all 1138)
id Title Authors Year
1
Robot-assisted retinal vein cannulation in an inA vivo porcine retinal vein occlusion model. ( 28084059 )
2017
2
Assessment of ischemia in acute central retinal vein occlusion from inner retinal reflectivity on spectral domain optical coherence tomography. ( 28053503 )
2017
3
Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion. ( 28085526 )
2017
4
Association of retinal vein occlusion, homocysteine, and the thrombophilic mutations in a Turkish population: A case-control study. ( 28085519 )
2017
5
Erratum to: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. ( 27957602 )
2017
6
BRANCH RETINAL VEIN OCCLUSION SECONDARY TO A RETINAL ARTERIOLAR MACROANEURYSM: A NOVEL MECHANISM SUPPORTED BY MULTIMODAL IMAGING. ( 28079651 )
2017
7
Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. ( 28031700 )
2017
8
Branch retinal vein occlusion: the importance of the topographical distribution of retinal vessels among risk factors. ( 28085135 )
2017
9
Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. ( 28447244 )
2017
10
Fernlike Maculopathy in a Patient With Central Retinal Vein Occlusion. ( 27281739 )
2016
11
Central Retinal Vein Occlusion and Paracentral Acute Middle Maculopathy Diagnosed With En Face Optical Coherence Tomography. ( 27631483 )
2016
12
MACULAR PERIVENOUS RETINAL WHITENING AND PRESUMED RETINO-CILIARY SPARING IN A RECURRENT CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH THE ANTIPHOSPHOLIPID SYNDROME AND CRYOGLOBULINEMIA. ( 27902540 )
2016
13
Optical Coherence Tomography Angiography in Central Retinal Vein Occlusion: Correlation Between the Foveal Avascular Zone and Visual Acuity. ( 27409478 )
2016
14
Spontaneous resolution of bilateral central retinal vein occlusion with cystoid macular oedema during pregnancy. ( 27879054 )
2016
15
SAFETY AND FEASIBILITY OF A NOVEL 25-GAUGE BIODEGRADABLE IMPLANT OF DEXAMETHASONE FOR TREATMENT OF MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION: A PHASE I CLINICAL TRIAL. ( 27632583 )
2016
16
Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. ( 27601878 )
2016
17
Relationship between metamorphopsia and foveal microstructure in patients with branch retinal vein occlusion and cystoid macular edema. ( 27169934 )
2016
18
Influence of hemorheological factors on the development of retinal vein occlusion. ( 27163689 )
2016
19
Poor outcomes despite aspirin or statin use in high-risk patients with retinal vein occlusion. ( 28004197 )
2016
20
Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. ( 27256303 )
2016
21
Central retinal vein occlusion as the initial presentation in leptomeningeal carcinomatosis. ( 27146934 )
2016
22
Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion. ( 27190640 )
2016
23
Management of Retinal Vein Occlusion, Who Is Responsible? ( 28033697 )
2016
24
Metamorphopsia Associated with Branch Retinal Vein Occlusion. ( 27123642 )
2016
25
Long-Term Functional and Anatomical Outcome of Radial Optic Neurotomy for Central Retinal Vein Occlusion. ( 27116505 )
2016
26
Central Retinal Artery Occlusion With Subsequent Central Retinal Vein Occlusion in Biopsy-Proven Giant Cell Arteritis. ( 27261946 )
2016
27
Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. ( 27401800 )
2016
28
Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. ( 27632214 )
2016
29
LYSOPHOSPHATIDIC ACIDS AND AUTOTAXIN IN RETINAL VEIN OCCLUSION. ( 27648638 )
2016
30
Correlation between optic nerve head circulation and visual function before and after anti-VEGF therapy for central retinal vein occlusion: prospective, interventional case series. ( 27044276 )
2016
31
Central Retinal Vein Occlusion Associated With Severe Vitamin D Deficiency. ( 27065380 )
2016
32
Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study. ( 27759857 )
2016
33
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients with Central Retinal Vein Occlusion. ( 27450625 )
2016
34
An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. ( 27319943 )
2016
35
Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema. ( 27160159 )
2016
36
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. ( 27401726 )
2016
37
Vitamin D Deficiency in Patients with Central Retinal Vein Occlusion: A Case Control Study. ( 27348601 )
2016
38
Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients. ( 27654837 )
2016
39
Re: Clark etA al.: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study (Ophthalmology 2016;123:330-6). ( 27664916 )
2016
40
ASSOCIATION BETWEEN RETINAL HEMORRHAGIC PATTERNS AND PERFUSION STATUS IN EYES WITH ACUTE CENTRAL RETINAL VEIN OCCLUSION. ( 27611056 )
2016
41
ASSOCIATIONS BETWEEN MACULAR EDEMA AND CIRCULATORY STATUS IN EYES WITH RETINAL VEIN OCCLUSION: An Adaptive Optics Scanning Laser Ophthalmoscopy Study. ( 28033234 )
2016
42
Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion. ( 28044102 )
2016
43
Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion. ( 26949616 )
2016
44
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (OzurdexAr) in its treatment. ( 27178087 )
2016
45
Retinal vein occlusion and risk of cerebrovascular disease and myocardial infarction: A meta-analysis of cohort studies. ( 26922716 )
2016
46
Risk of Retinal Vein Occlusion Following End-Stage Renal Disease. ( 27100450 )
2016
47
Response to: 'Comment on Central retinal vein occlusion: modifying current treatment protocols'. ( 27101756 )
2016
48
Frosted Branch Angiitis Secondary to Familial Mediterranean Fever Resembling Central Retinal Vein Occlusion. ( 28044118 )
2016
49
OUTER RETINAL LAYER CHANGES AFTER DEXAMETHASONE IMPLANT FOR CENTRAL RETINAL VEIN OCCLUSION. ( 28030428 )
2016
50
Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension. ( 27878430 )
2016

Variations for Retinal Vein Occlusion

Expression for Retinal Vein Occlusion

Search GEO for disease gene expression data for Retinal Vein Occlusion.

Pathways for Retinal Vein Occlusion

GO Terms for Retinal Vein Occlusion

Sources for Retinal Vein Occlusion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....